Brooklyn ImmunoTherapeutics Inc News - BTX

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...

Initial Statement of Beneficial Ownership (3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE...

BioTime Announces Appointment of General Counsel

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs...

BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE...

BioTime Reports First Quarter 2019 Financial Results and Provides Business Update

Positive OpRegen® Data Presented at Association for Research in Vision and Ophthalmology Annual Meeting Announced Issuance of New...

BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet needs, announced...

BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, today announced that...

Current Report Filing (8-k)

UNITED STATES SECURITIES AND EXCHANGE...

BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision & Ophthalmo...

Treatment with OpRegen® Continues to be Well Tolerated with Signs of Structural Improvement in the Retina Observed in Some Patients...

BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy & Repair Confe...

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Brooklyn ImmunoTherapeutics Inc (BTX)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

BTX News

Statement of Changes in Beneficial Ownership (4)

Initial Statement of Beneficial Ownership (3)

BioTime Announces Appointment of General Counsel

BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®

Current Report Filing (8-k)

Current Report Filing (8-k)

BioTime Reports First Quarter 2019 Financial Results and Provides Business Update

BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury

BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019

Current Report Filing (8-k)

BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision & Ophthalmo...

Amended Annual Report (10-k/a)

Amended Annual Report (10-k/a)

Current Report Filing (8-k)

BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy & Repair Confe...

BTX Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Brooklyn ImmunoTherapeutics Inc (BTX) News

Brooklyn ImmunoTherapeutics Inc (BTX)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

BTX News

Statement of Changes in Beneficial Ownership (4)

Initial Statement of Beneficial Ownership (3)

BioTime Announces Appointment of General Counsel

BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen®

Current Report Filing (8-k)

Current Report Filing (8-k)

BioTime Reports First Quarter 2019 Financial Results and Provides Business Update

BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury

BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019

Current Report Filing (8-k)

BioTime Presents Updated Data from OpRegen® Phase I/IIa Clinical Study at the Association for Research in Vision & Ophthalmo...

Amended Annual Report (10-k/a)

Amended Annual Report (10-k/a)

Current Report Filing (8-k)

BioTime to Present SCiStar Clinical Study Top-Line Data at the 26th Annual American Society for Neural Therapy & Repair Confe...

BTX Discussion

Your Recent History